Search Results - "Wiegert, E"

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study by Thomas, M., Ponce-Aix, S., Navarro, A., Riera-Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Dómine Gómez, M., Kollmeier, J., Sadjadian, P., Fröhling, K -P, Huber, R.M., Wolf, M., Pall, Georg, Surmont, Veerle, Bosquee, Léon, Germonpré, Paul, Brückl, Wolfgang, Grah, Christina, Herzmann, Christian, Leistner, Rumo, Meyer, Andreas, Müller, Lothar, Schmalz, Oliver, Scholz, Christian, Schröder, Michael, Serke, Monika, Wesseler, Claas, Brandts, Christian, Kopp, Hans-Georg, Blau, Wolfgang, Griesinger, Frank, Campelo, Maria Rosario Garcia, Garcia, Yolanda Garcia, Perez, José Manuel Trigo

“…The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve…”
Get full text

Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study by Thomas, M., Ponce Aix, S., Navarro Mendivil, A., Riera Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Mauri, C., Domine Gomez, M., Kollmeier, J., Sadjadian, P., Fröhling, K.-P., Huber, R.M., Wolf, M.

Get full text

Characterization of Euglenaformis gen. nov. and the chloroplast genome of Euglenaformis [Euglena] proxima (Euglenophyta) by Bennett, Matthew S., Wiegert, Krystle E., Triemer, Richard E.

“…Euglena proxima is a common, globally dispersed, and easily identified photosynthetic euglenoid. Previous phylogenetic analyses using nuclear-encoded small…”
Get full text

Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti‐neutrophil cytoplasmic antibodies (ANCA) by SPECKS, U., WIEGERT, E. M., HOMBURGER, H. A.

“…We have expressed conformationally intact, enzymatically active recombinant PR3 in HMC‐1 cells (HMC‐1/PR3 cells) that is recognized by C‐ANCA. Here we directly…”
Get full text

Tracing Patterns of Chloroplast Evolution in Euglenoids: Contributions from Colacium vesiculosum and Strombomonas acuminata (Euglenophyta) by Wiegert, Krystle E., Bennett, Matthew S., Triemer, Richard E.

“…The chloroplast genomes of two photosynthetic euglenoids, Colacium vesiculosum Ehrenberg (128,889 bp), and Strombomonas acuminata (Schmarda) Deflandre…”
Get full text

Evolution of the Chloroplast Genome in Photosynthetic Euglenoids: A Comparison of Eutreptia viridis and Euglena gracilis (Euglenophyta) by Wiegert, Krystle E., Bennett, Matthew S., Triemer, Richard E.

“…The chloroplast genome of Eutreptia viridis Perty, a basal taxon in the photosynthetic euglenoid lineage, was sequenced and compared with that of Euglena…”
Get full text

Comparative chloroplast genomics between Euglena viridis and Euglena gracilis (Euglenophyta) by Bennett, Matthew S., Wiegert, Krystle E., Triemer, Richard E.

“…Bennett M.S., Wiegert K.E. and Triemer R.E. 2012. Comparative chloroplast genomics between Euglena viridis and Euglena gracilis (Euglenophyta). Phycologia 51:…”
Get full text

Pool Chemical–Associated Health Events in Public and Residential Settings—United States, 1983-2007 by Sackett, DC, Wiegert, EJ, Egan, JS, Nicholas, DC, Hlavsa, MC, Beach, MJ, Gilchrist, J

“…Swimming pool chemicals are added to the water in these venues to prevent transmission of infectious pathogens. These chemicals can cause injury when handled…”
Get full text

Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors by Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T.R.J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., Bexon, A.

Get full text

LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors by Haanen, J., Mackensen, A., Koenecke, C., Alsdorf, W., Desuki, A., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Wiegert, E., Schulz, C., Rengstl, B., Preußner, L., Türeci, Ö., Sahin, U.

Get full text

Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers by Yang, P, Cunningham, J M, Halling, K C, Lesnick, T G, Burgart, L J, Wiegert, E M, Christensen, E R, Lindor, N M, Katzmann, J A, Thibodeau, S N

“…Microsatellite instability (MSI) is a genomic alteration observed in 15-30% of colorectal cancer (CRC). Two MSI phenotypes have been defined for CRC: MSI-H is…”
Get full text

LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours by Mackensen, A., Haanen, J.B.A.G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., Müller, F., Desuki, A., Lüke, F., Wiegert, E., Flemmig, C., Schulz-Eying, C., Rengstl, B., Preussner, L., Türeci, Ö., Sahin, U.

Get full text

LBA33 - Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial by Cunningham, D., Salazar, R., Sobrero, A., Ducreux, M.P., Van Cutsem, E., Scheithauer, W., Tournigand, C., Molnar, V., Starke, M., Baumann, M., Wiegert, E., Schmidt, M., Arnold, D.

“…The TLR9 agonist lefitolimod broadly activates the innate and adaptive immune system. Based on encouraging data from the randomized phase II IMPACT trial,…”
Get full text

Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial by Cunningham, D., Salazar, R., Sobrero, A., Ducreux, M.P., Van Cutsem, E., Scheithauer, W., Tournigand, C., Molnar, V., Starke, M., Baumann, M., Wiegert, E., Schmidt, M., Arnold, D.

Get full text

LBA33Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial by Cunningham, D, Salazar, R, Sobrero, A, Ducreux, M P, Van Cutsem, E, Scheithauer, W, Tournigand, C, Molnar, V, Starke, M, Baumann, M, Wiegert, E, Schmidt, M, Arnold, D

“…Abstract Background The TLR9 agonist lefitolimod broadly activates the innate and adaptive immune system. Based on encouraging data from the randomized phase…”
Get full text

Transcriptome-enabled marker discovery and mapping of plastochron-related genes in Petunia spp by Guo, Yufang, Wiegert-Rininger, Krystle E, Vallejo, Veronica A, Barry, Cornelius S, Warner, Ryan M

“…Petunia (Petunia × hybrida), derived from a hybrid between P. axillaris and P. integrifolia, is one of the most economically important bedding plant crops and…”
Get full text

A Root-Expressed l-Phenylalanine: 4-Hydroxyphenylpyruvate Aminotransferase Is Required for Tropane Alkaloid Biosynthesis in Atropa belladonna by Bedewitz, Matthew A., Góngora-Castillo, Elsa, Uebler, Joseph B., Gonzales-Vigil, Eliana, Wiegert-Rininger, Krystle E., Childs, Kevin L., Hamilton, John P., Vaillancourt, Brieanne, Yeo, Yun-Soo, Chappell, Joseph, DellaPenna, Dean, Jones, A. Daniel, Buell, C. Robin, Barry, Cornelius S.

“…The tropane alkaloids, hyoscyamine and scopolamine, are medicinal compounds that are the active components of several therapeutics. Hyoscyamine and scopolamine…”
Get full text

Rapid capillary electrophoretic analysis of human serum proteins: qualitative comparison with high-throughput agarose gel electrophoresis by Clark, R., Katzmann, J.A., Wiegert, E., Namyst-Goldberg, C., Sanders, L., Oda, R.P., Kyle, R.A., Landers, J.P.

“…This study details the qualitative results from a comparative evaluation of agarose gel electrophoresis (AGE) and (CZE) as a screening procedure for monoclonal…”
Get full text

Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma by Cunningham, D., Van Cutsem, E., Salazar, R., Ducreux, M., Scheithauer, W., Sclafani, F., Wiegert, E., Schmidt, M., Tournigand, C., Sobrero, A., Arnold, D.

Get full text

1672PMaintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study by Thomas, M, Ponce Aix, S, Navarro Mendivil, A, Riera Knorrenschild, J, Schmidt, M, Wiegert, E, Kapp, K, Mauri, C, Domine Gomez, M, Kollmeier, J, Sadjadian, P, Fröhling, K-P, Huber, R M, Wolf, M

Get full text